MedPath

Analgesia Nociception Index Guided Remifentanil Administration During Propofol Anesthesia for Laparoscopic Surgery

Not Applicable
Terminated
Conditions
General Anesthesia
Registration Number
NCT01893723
Lead Sponsor
University Hospital, Lille
Brief Summary

The Physiodoloris (MetroDoloris, Lille, France) monitor, CE marqued, uses the ECG signal in order to compute the Analgesia Nociception Index (ANI) which has been shown to measure the relative parasympathetic tone, and hence to reflect the analgesia/nociception balance during general anesthesia. The primary endpoint of this randomized multicenter study is to measure whether there is a benefit to use the ANI in order to adapt remifentanil administration during propofol anesthesia for laparoscopic surgery. Primary endpoint : lesser proportion of patients presenting with at least one episode of hemodynamic reactivity, hypotension or bradycardia in the ANI guided group vs control group ?

Detailed Description

The Physiodoloris (MetroDoloris, Lille, France) monitor, CE marqued, uses the ECG signal in order to compute the Analgesia Nociception Index (ANI) which has been shown to measure the relative parasympathetic tone, and hence to reflect the analgesia/nociception balance during general anesthesia. The primary endpoint of this randomized multicenter study is to measure whether there is a benefit to use the ANI in order to adapt remifentanil administration during propofol anesthesia for laparoscopic surgery. Primary endpoint is: lesser proportion of patients presenting with at least one episode of hemodynamic reactivity, hypotension or bradycardia in the ANI guided group vs control group ?

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
37
Inclusion Criteria
  • laparoscopic cholecystectomy or gynecological laparoscopic surgery
  • ASA I or II
  • adult patient
  • body mass index between 17 and 33 kg/m2
Exclusion Criteria
  • pregnancy
  • arrhythmia
  • pace maker
  • diabetes mellitus
  • dysautonomia
  • treatment with beta blocking agents

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Proportion of patients presenting at least once with hemodynamic reactivity, hypotension or bradycardiaend of surgery (around 60 to 90 min after start)
Secondary Outcome Measures
NameTimeMethod
total administered remifentanilend of surgery
number of target changesend of surgery (around 60 to 90 min after start)
morphine sulfate total administration after end of surgeryduring two hours after end of surgery
Visual Analog Scale evaluation of pain after surgeryduring two hours after end of surgery
number of bradycardia and hypotensionfrom start to end of surgery (around 60 to 90 min )
ANI measure during surgeryfrom start to end of surgery (around 60 to 90 min)
total administered dose of ephedrinebetween start and end of anesthesia

Trial Locations

Locations (5)

University Hospital Erasme (ULB)

🇧🇪

Brussel, Belgium

Clinique privée d'ANTONY

🇫🇷

Antony, France

University Hospital Claude Huriez

🇫🇷

Lille, France

University Hospital Roger Salengro

🇫🇷

Lille, France

University Hospital

🇫🇷

Saint Etienne, France

University Hospital Erasme (ULB)
🇧🇪Brussel, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.